Arerugi. 2024;73(3):268-278. doi: 10.15036/arerugi.73.268.
[Article in Japanese]


Background: In 2022, the "New Capitalism Grand Design and Implementation Plan" was adopted in Japan, emphasizing the promotion and environmental development of startups. Given this context, an investigation into the startup and investment landscape in the allergy sector, both domestically and internationally, becomes imperative.

Methods: We analyzed 156 allergy-related startups from Japan, the US, and Europe from 2010 to 2021. Data on corporate information and investment trends were extracted from databases and VC websites.

Results: The total investment reached approximately 7.2 billion USD, with a ratio of 20:6:1 for the US, Europe, and Japan, respectively. The US showed a decline post its peak from 2016-2018, while Europe and Japan experienced growth. Notably, the US primarily invested in biopharmaceuticals for atopic dermatitis and food allergies, Europe in asthma-related apps, and Japan in healthcare apps and cross-border startups.

Discussion and conclusion: While Japan's investment environment in the allergy sector remains in its nascent stages and has room for development, the US and Europe are evidently ahead. Considering the rise of startups and funding limitations in Japan, external funding from regions like the US becomes a potential avenue. These findings are anticipated to contribute to the strategic activation of startups in allergy research and development.

Keywords: allergy; immunology; investment; startup; venture capital.

Publication types

  • English Abstract

MeSH terms

  • Allergy and Immunology* / economics
  • Europe
  • Humans
  • Hypersensitivity / immunology
  • Hypersensitivity / therapy
  • Investments
  • Japan
  • United States